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cancer, the median survival was 4,1 years. The potential to improve 
survival coupled with the fact that most second primary lung cancers 
are asymptomatic at the time of diagnosis suggest that careful post-
operative surveillance of patients with early stage non-small cell lung 
cancer is warranted. 
In patients with synchronous cancers located in different lungs, a staged 
bilateral thoracotomy at an interval of 4 to 6 weeks is recommended. 
It seems logical to start at the side with the higher stage of the disease. 
When a complete resection was performed, the contralateral side can be 
explored and eventually resected. 
Conclusion
The management of patients in whom a second primary lung cancer 
develops remains a challenging problem. However, there appears to be 
a beneﬁt from surgical resection in well selected patients. 
Prognosis after resection of a synchronous tumour is substantially 
lower compared to prognosis after resection of a metachronous lesion. 
An exception are satellite nodules in the same lobe which have a better 
prognosis after resection.
Because accurate differentiation of synchronous or metachronous 
tumours from intrapulmonary metastasis or recurrent lung cancer is not 
always clinically possible, patients with adequate pulmonary and physi-
ologic reserve should undergo surgical resection of the second lesions 
after careful staging. 
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Treatment for the screen-detected lung cancer: characteristics and 
outcome
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Japan
Owing to the advent of reﬁned chest CT images with higher resolution 
and CT screening programs, smaller lung cancers are being discovered 
in asymptomatic patients. Most of them are more often found on a 
low-dose CT images, and they tend to have characteristic appearance 
on high-resolution CT scan as ground glass opacity (GGO), a focal 
intermediate/mild increase in the CT density. Of course, the screening 
program is still picking up the more solid tumors with/without lymph 
node involvement, the percentage of GGO or GGO-like lesions is 
obviously increased in low-dose CT screening era. These GGO tumors 
are pathologically characterized by the morphology of non-/minimally 
invasive form of well-differentiated adenocarcinoma termed as bron-
chioloalveolar carcinoma (BAC) of the non-mucinous type. 
The superb prognosis of these GGO-BAC tumors is being recognized 
in the surgical community. Although the gold standard operation for 
peripheral lung cancer has been lobectomy with lymph node sampling/
dissection, the revision is thought to be necessary, especially for these 
screen-detected GGO-BAC tumors. The possibility of limited resection 
such as segmentectomy/wedge resection seems to be realistic. Enough 
number of institutional reports describing the equivalent surgical 
outcome by limited resection have been accumulated. Therefore, the 
randomized phase III trial between lobectomy and limited resection is 
being planned both in US and Japan in a non-inferiority design setting. 
The results of these studies might be applied in the management of 
screen-detected, small-sized tumors in the near future.
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Approximately 40,000 patients / year are diagnosed with Stage III 
NSCLC. The cure rate with surgery or radiation therapy alone is less 
than 10%. There is signiﬁcant local failure with bimodality treatment. 
Treatments include concurrent chemoradiation or chemotherapy fol-
lowed by surgery. Trimodality therapy is both attractive and feasible. 
We have results from several trials available including SWOG 8805 
(stage IIIA & IIIB), INT 0160 (Pancoast ) and radiation therapy limited 
to 45 Gy. 
Current protocols studying the importance of mediastinal lymph node 
clearance are SWOG 8805; Brigham & Womens (Bueno et al., 2000); 
and CALGB 8935. The importance of pathologic complete response 
was studied by INT 0139. The University of Maryland study found 
high-dose radiation treatments to be attractive and feasible.
Residual disease is frequently present after chemoradiotherapy. This 
viable tumor may be the only disease present and resection may lead to 
cure. The incidence of local recurrence is signiﬁcant. Actual experience 
conﬁrms these assumptions. Dillman et al., in CALGB #8433î found 
median survival improved with chemotherapy. Using radiation therapy 
alone median survival was 9.7 months. Chemotherapy and radiation re-
sulted in median survival of 13.8 months. With OS improved at 7 years, 
6% with radiation alone and 13% with chemotherapy and radiation. 
(Furuse et al. J Clin Oncol 17:2692-99, 1999).
Trimodality was studied using PE x 2 cycles with XRT (45Gy) Fol-
lowed by Surgical resection in 126 Pathologic IIIa (N2) =60%, and 
pathologic IIIb = 40%. 3 year survival for IIIa = 27% and IIIb was 
24%. 5 year survival was 23% vs 21%. Pathologic complete response 
was 21% and microscopic foci were present only in 37%. A major 
path response was seen in 58%. Patients with lymph node involvement 
showed an improved survival. Grade 4 toxicity was evident in13%; 
Mortality rate was 6%. The brain was the major site of relapse in 40%; 
the sole site in 10%. INT0139 was a phase III Comparison of Chemo-
radiotherapy vs Chemoradiotherapy followed by Surgery in IIIa (N2) 
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NSCLC. (Update ASCO 2005 ì Progression free Survival by Treatment 
Armsî) Treatment-Related Deaths were related to type of Surgery. 
Lobectomy (r/l)1/98 (1%) Pneumonectomy 14/54 (26%).
The rationale for Escalated Radiotherapy Concurrent with Chemother-
apy: Extensive experience demonstrates that the rate of local control is 
low with sequential chemoradiotherapy (Le Chevalier, 1991) or with 
concurrent chemotherapy and radiation therapy with 45 Gy (8805). 
Modern radiotherapy techniques combined with improved surgical 
experience allow for use of 60 Gy concurrent with chemotherapy 
as preoperative treatment. In a series at the University of Maryland, 
patients received treatment with radiosensitizing chemotherapy (usually 
BDCA/Paclitaxel). They received 59 Gy radiation using 3D conformal 
therapy. Surgery was lobectomy/pneumonectomy 4 weeks after treat-
ment concluded. Results: 85% (70%-94%) were downstaged pathologi-
cally; 83% (67%-93%) cleared the mediastinum. 45% (29%-61%) had 
a complete pathologic response. MST, OS - Not reached with median 
f/u of > 2 years
This was followed by GCC 9953:TRIMODALITY THERAPY FOR 
IIIA / IIIB NSCLC. 33 PTS (1 INELIGIBLE) with a M:F-11:22. Stage 
was T4- 5; N2-18; N3- 8. FAILURES-15 LOCOREGIONAL ONLY- 
1 DISTANT/BOTH -14 (brain in 5). SURGERY was performed 4-8 
weeks after chemoXRT. ALL patients UNDERWENT Bronch/MED, 
then REMEDiastinoscopy or VATS RESTAGING. 32 underwent 
RESECTION ; MED CLEARANCE was found in12/32. PATH CR 
occurred in 5/32. INT0139 was a Phase III Comparison of Chemora-
diotherapy vs Chemoradiotherapy followed by Surgery in IIIa (N2) 
NSCLC.
Type of Surgery was related to Cause of Death. (L) Lobectomy was 
associated with/ 1/98 deaths (1%) from PE. (R) Bilobectomy had 1 
patient who died of ARDS. Pneumonectomy on the other hand was as-
sociated with an inordinately high perioperative mortality14/54 (26%). 
Rationale for Escalated Radiotherapy Concurrent with Chemotherapy 
Extensive experience demonstrates that the rate of local control is 
low with sequential chemoradiotherapy (Le Chevalier, 1991) or with 
concurrent chemotherapy and radiation therapy with 45 Gy (8805). 
Modern radiotherapy techniques combined with improved surgical 
experience allow for use of 60 Gy concurrent with chemotherapy as 
preoperative treatment. Patients received treatment with radiosensitiz-
ing chemotherapy (usually BDCA/ Paclitaxel). They received 59 Gy 
radiation using 3D conformal therapy. Surgery was lobectomy/pneumo-
nectomy 4 weeks after treatment concluded.
Preop chemorads for IIIA:Results
85% (70%-94%) downstaged pathologically
83% (67%-93%) cleared mediastinum
45% (29%-61%) with complete pathologic response
10% (3%-24%) with any local recurrence
MST, OS - Not reached with median f/u of > 2 years
GCC 9953:TRIMODALITY THERAPY FOR IIIA / IIIB NSCLC
33 PTS-1 INELIGIBLE
M:F-11:22
T4- 5; N2-18; N3- 8
FAILURES-15
LOCOREGIONAL ONLY- 1
DISTANT/BOTH - 14
BRAIN - 5
GCC 9953:TRIMODALITY IIIA NSCLC
SURGERY 4-8 weeks after chemoXRT
ALL UNDERWENT B/MED, then
REMED/ VATS RESTAGING
32 RESECTION
MED CLEARANCE 12/32
PATH CR 5/32
COMPLICATIONS- 2 MINOR; 1 MAJOR (VENT)
Bronchial stumps WERE covered with intercostal muscle ﬂaps. THE 
Serrattus anterior WAS USED AS A FLAP FOR pneumonectomies. 
Limited intraoperative ﬂuid administration WAS USED TO AVOID 
PULMONARY EDEMA. Barotrauma to contralateral lung WAS 
limited during single lung ventilation by limiting peak pressure and 
ventilatory volume AND UTILIZING Early extubation. Difﬁculties 
with pneumonectomy in trimodality THERAPY SPECIFICALLY 
INCLUDE Signiﬁcant loss of respiratory capacity, A Dissection THAT 
WAS difﬁcult AND SOMETIMES hazardous. Increased susceptibility 
to infection, AND Impaired healing of bronchial stump CAN LEAD 
TO bpf and or empyema. Again to avoid this mucsles ﬂaps are rou-
tinely employed.
The data on trimodality with pneumonectomy unfortunately are tainted 
by 2 studies with poor results in this subgroup. Cisplatin / etoposide and 
45 Gy followed by resection was used in the intergroup study (0139). 
This resulted in a High mortality (26%) after pneumonectomy and there-
fore Reduced overall survival after pneumonectomy. In our series the 
Clinical Results and Complications were as ﬁollows: in 26 patients un-
dergoing opneumonectomy after high dose chemoradiation , All patients 
were discharged alive from the hospital. The Length of stay was 3 - 47 
days (mean 8.6 days). 14 patients had complications: 1 had an esopha-
geal stricture secondary to XRT which required dilatation. 3 patients and 
vocal cord paralysis. One had severe hypotension. 4 developed pneumo-
nia / respiratory distress. 2 had supraventricular dysrhythmias requiring 
Rx.1 had an upper extremity DVT. 2 had post-thoracotomy syndrome. 
The overall median survival has not yet been reached!
Surgical Considerations in trimodality includecovering the bronchial 
stumps with intercostal muscle ﬂap; Serrattus ant ﬂaps were used in 
pneumonectomies. Limited intraoperative ﬂuid administration was 
used. Barotrauma to the contralateral lung was limited during single 
lung ventilation by limiting peak pressure and ventilatory volume. 
Early extubation was utilized routinely. ICMF HARVEST is performed 
at the time of the thoracotomy.
Pneumonectomy after high dose chemoradiation was reported by 
Gamliel et al with excellent r esults. Despite previous studies with 
high motality after chemoradiation, especially with right sided surgery, 
excellent survival with low perioperative morbidity and mortality 
was described. The difﬁculties with pneumonectomy after trimodal-
ity include signiﬁcant loss of respiratory capacity; difﬁcult dissection 
and hazardous; there is increased susceptibility to infection and even 
greater impaired healing of the bronchial stump. Therefore broncho-
pleural ﬁstula and empyema are more common.
All patients were discharged alive from the hospital after a length of 
stay of 3 - 47 days(mean 8.6 days). There were 14 patients who had 
complications:
1 - esophageal stricture 2˚ XRT requiring dilatation; 3 vocal cord 
paralysis; 1 ñ hypotension; 4 pneumonia / respiratory distress; 2 
supraventricular dysrhythmias requiring Rx; 1 upper extremity DVT; 2 
post-thoracotomy syndrome.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS152
Pancoast Tumors are another subgroup often requiring Trimodality Rx. 
In SWOG/ INT 0160 induction chemoXRT were given followed by 
resection. 111 eligible patients who were med negative including T3-4 
/ N0-1. 80 (72.1%) were T3; 31 were T4 tumors. 2 cycles of cisplatin/
etoposide W/ 45 Gy of radiation were given. There were 3 treatment 
deaths (2.7%). 95 pts were eligible for surgery (85%); 83 underwent 
thoracotomy (75%) 2 (2.4%) died postoperatively. 76 (92%) under-
went complete resection. 54 (65%) specimens showed complete/partial 
response. 2-year survival was 55%; 70% survival if complete resection 
was achieved. Finally, the role of high dose trimodality therapy for 
Superior Sulcus tumors was studied by Kwong KF, Gamliel Z, Krasna 
MJ. 36 patients with Pancoast tumor Stage IIB-IV (solitary brain met) 
were treated. R0 resection was achieved in 36 (97.3%) patients. Opera-
tive mortality was 2.7% (n = 1). High-dose radiotherapy (mean 56.9 
Gy; range, 30-70.2 Gy) was successfully tolerated in all but 1 patient. 
Pathologic complete response was found in 40.5% (n = 15) of patients. 
Session M02: Translational Research in 
Radiation Oncology
M02-01 Translational Research in Radiation Oncology, Mon, Sept 3, 10:30 - 12:00
FDG-PET and tumor response
Mac Manus, Michael P. 
Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
Introduction: Structural imaging using CT scanning has long been the 
standard investigation for response assessment after chemotherapy, 
neoadjuvant chemoradiation or deﬁnitive radiation therapy (RT) for 
both non-small cell (NSCLC) and small cell lung cancer (SCLC). 
Changes in tumor dimensions after therapy are categorized into 
the widely-used WHO and RECIST response categories, which 
have prognostic signiﬁcance. However, CT scanning suffers from 
well-known limitations. These limitations include the relatively 
slow rate of change often observed in tumor volume after effective 
therapy, dependence on the unreliable parameter of lymph node size 
to determine involvement by tumor and an inability to distinguish 
between inactive scarring or necrotic tumor and active tumor in 
residual masses after therapy. The utility of CT may be further reduced 
by the presence of radiation pneumonitis and atelectasis, which can 
make it impossible to measure tumor size. 
Increasing numbers of studies demonstrate that functional imaging with 
18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) 
can be more accurate for early assessment of response to treatment 
of NSCLC than structural imaging. FDG is a glucose analogue that is 
taken up and trapped at a high rate by malignant tumor cells, especially 
those of NSCLC. After intravenous injection of FDG labeled with the 
positron emitting isotope 18F, most lung cancers can be imaged using 
a PET scanner. Changes in FDG uptake after therapy may precede 
changes in tumor volume and therefore, comparison of pre and post 
therapy PET scans can provide an early semiquantitative indication of 
response.
FDG-PET Response Assessment Methodology
Therapeutic response information provided by PET is more complex 
than that provided by structural imaging and researchers continue 
to search for the best way to use it. Uptake of FDG into tumors is 
inﬂuenced by many different biological factors, including substrate 
utilization, tumor perfusion, effects of hypoxia and apoptosis , the 
viable cell fraction, the extent of inﬂammatory cell inﬁltrate and 
oncogene expression. PET scanning allows the investigator to visualize 
and measure the intensity of residual metabolic activity within a lesion 
as well as estimating its size, especially if PET/CT is used rather than 
PET alone. The feature that really distinguishes PET from structural 
imaging is its ability to integrate the effects of residual tumor volume 
and residual tumor metabolic activity into a single response assessment. 
The best methodology for determining early PET response has not yet 
been established but there are two main approaches.
Visual /Qualitative Methods
After deﬁnitive therapy, a visual estimate of response can give extreme-
ly useful prognostic information. This method is simple and widely-
used, especially in the lymphomas. It relies on the skilled perceptions 
of an experienced human observer and compares metabolic activity in 
all lesions when pre- and post-treatment PET scans, performed under 
identical conditions, are displayed side by side. Absence of residual 
uptake of FDG, or reduction in intensity of uptake to no more than that 
contained in the blood pool, denotes a complete metabolic response 
or CMR. An appreciable reduction in the intensity of uptake, in the 
absence of any new lesions, is denoted as a partial metabolic response 
or PMR. Progressive metabolic disease, or PMD, denotes any site of 
progression and if there is no appreciable change the term stable meta-
bolic disease (SMD) is used.
Semiquantitative or SUV-based Methods
There are very many possible methods for quantitative assessment of 
response to therapy based on PET 1, ranging from the simple to the 
extremely complex. None of the more complex methods has been 
widely adopted and the only parameter with widespread acceptance 
as a semiquantitative measure of lesion intensity is the standardized 
uptake value or SUV. The most commonly used SUV parameter is the 
SUVmax, derived from tissue activity at a single point in time and us-
ing the pixel with highest lesion activity. This analysis is not dependent 
on acquisition of dynamic information of the type required for kinetic 
modeling approaches. SUV measurement is affected by a variable time 
between injection and scan, by variation in time to equilibrium and by 
variation in uptake curve slope before and after therapy. Additionally 
it may be affected by blood glucose concentration, differs if weight 
or body surface area is used as a correction factor and may not give 
the same results if different scanners used. Additionally, inﬂammatory 
reactions (infection, radiation) in normal tissues may produce SUV in 
“malignant” range (SUV > 2.5). However, the absolute accuracy of the 
SUV measurement may not be a confounding factor in assessment of 
treatment response using FDG-PET if the pre- and post-treatment scans 
are performed on the same scanner under identical conditions. This 
type of assessment may give the earliest measure of response and be 
the best available method for determining response to chemotherapy or 
to neoadjuvant therapy when insufﬁcient time has elapsed for responses 
to evolve fully after therapy.
Clinical studies of PET response in NSCLC
PET Response after deﬁnitive Radiation Therapy/Chemoradiation
Data from prospective studies at Peter MacCallum Cancer Centre have 
shown that PET is superior to CT in response assessment after chemo-
radiation for NSCLC. PET and CT responses were identical in only 
40% of cases 2. Additionally, PET response was correlated powerfully 
with survival and patterns of failure 3. Pre- and post-treatment FDG-
PET scans were compared for 88 patients after concurrent platinum-
based radical chemo/RT (n=73) or radical RT alone (n=15). Follow-up 
